PRT3789 is a first-in-class targeted protein degrader of SMARCA2. Selective targeting of SMARCA4 (BRG1) deleted tumors provides a defined patient selection strategy.
About
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.